Results 81 to 90 of about 142 (121)

Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications

Frontiers in Cellular and Infection Microbiology
Candida auris is an invasive fungal pathogen recognized globally as a significant health threat due to its marked resistance to multiple classes of antifungal agents, including azoles, echinocandins, and polyenes.
Wei Du, Qihui Wang, Min Zhao
doaj   +1 more source

Intravitreal rezafungin and anidulafungin in a rabbit model of Aspergillus fumigatus endophthalmitis

Scientific Reports
Abstract Rezafungin (RZF) and anidulafungin (AFG) are echinocandins with potential for treating Aspergillus fumigatus endophthalmitis. We evaluated their antifungal and anti-inflammatory effects in vitro and in a rabbit endophthalmitis model.
Yue Zhang, Yanjie Zhou, Yi Tang, Hong Wu
openaire   +1 more source

P-1958. Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin

Open Forum Infectious Diseases
Abstract Background Rezafungin (RZF), a novel long-acting intravenous echinocandin, was approved by the FDA in March 2023 for adult patients (pts) with candidemia and invasive candidiasis and safety data for up to 4 weekly doses.
Hengel, Richard L, Metzger, Brian S, Young, Erika M, Stock, Kent J, John, Joseph F, Couch, Kimberly A, Weeks, Christina J, Van Anglen, Lucinda J   +7 more
openaire   +1 more source

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks

Frontiers in Cellular and Infection Microbiology
Candida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C.
Xuewei Du, Li Li
doaj   +1 more source

Rezafungin in fluconazole-resistant and refractory candidiasis: the first Brazilian experience

Revista do Instituto de Medicina Tropical de São Paulo
ABSTRACT Invasive candidiasis is associated with high morbidity and mortality, and the rising of antifungal resistance underscores the need for new therapies. Rezafungin, a second-generation echinocandin, enables once-weekly dosing, achieves high plasma concentrations, and shows potent in vitro activity.
Kruschewsky, Wdson Luis Lima, Nakagawa, Jeanne Aiko de Souza, Siqueira, Lumena Pereira Machado, Taborda, Mariane, de Oliveira, Vítor Falcão, Abdala, Edson, Magri, Adriana Satie Gonçalves Kono, Magri, Marcello Mihailenko Chaves   +7 more
openaire   +4 more sources

Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment

Pathogens
Candidemia is a highly prevalent invasive fungal infection caused primarily by C. albicans, C. parapsilosis, C. glabrata (currently Nakaseomyces glabratus), C. tropicalis, and C. krusei (currently Pichia kudriavzevii). Risk factors for the development of
Juan Pablo Cabrera-Guerrero, Eduardo García-Salazar, Graciela Hernandez Silva, Alberto Chinney Herrera, Erick Martínez-Herrera, Rodolfo Pinto-Almazán, María Guadalupe Frías-De-León, Carlos Alberto Castro-Fuentes   +7 more
doaj   +1 more source

Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro

Journal of Antimicrobial Chemotherapy
Abstract Objectives We sought to evaluate the comparative activity of rezafungin compared with caspofungin and other antifungal classes against biofilms from a large clinical panel of Candida strains (n = 167). Methods
Hafsa Abduljalil, Kerry Bartie, Abhijit M Bal, Riina Rautemaa-Richardson, Craig Williams, Ryan Kean, Gordon Ramage   +6 more
openaire   +5 more sources

Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children

Brazilian Journal of Infectious Diseases
Background: Invasive candidiasis, including candidemia and deep-seated Candida infections, remains a major cause of morbidity and mortality in hospitalized patients worldwide, particularly in low- and middle-income countries.
Arnaldo L. Colombo, Marcello M.C. Magri, Fabianne Carlesse, Diego R. Falci, Marcia Garnica, Daniel W.C.L. Santos, Flavio Queiroz-Telles, Alessandro C. Pasqualotto   +7 more
doaj   +1 more source

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis

Infection and Drug Resistance
Anna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj  

Update on therapeutic approaches for invasive fungal infections in adults

Therapeutic Advances in Infectious Disease
Invasive fungal infections are increasingly encountered with the expansion of iatrogenic immunosuppression, including not only solid organ and hematopoietic stem cell transplant recipients but also patients with malignancies or autoimmune diseases ...
Catherine-Audrey Boutin, Me-Linh Luong
doaj   +1 more source